Introduction
Lung cancer remains the leading cause of cancer-related mortality in the western world, and is projected to account for 28% of all cancer deaths in the United States in 2012 [1] . Non-small cell lung cancer (NSCLC) represents 80-85% of all lung cancers, and surgical resection of early stage disease presents the best opportunity for long term survival [2] . Despite extensive research efforts, the prognosis of NSCLC patients, even with complete surgical resection, remains disappointing [3] . Immunotherapy has shown potential impact in the treatment NSCLC, and clinical studies on the significance of immunological markers are warranted [4] .
The immune system can be divided into two compartments, the innate and the adaptive immune systems. The innate system consists of dendritic cells (DCs), natural killer (NK) cells, NK T cells, macrophages, neutrophils, basophils and eosinophils, and is the body's first line of defense against pathogens. B cells, CD4+ T helper cells and CD8+ cytotoxic T cells, express a diverse set of somatically generated antigen-specific receptors, thereby enabling the highly specific adaptive immune response [5] .
Tumor-promoting inflammation mediated by cells of the innate immune system is recognized as an enabling characteristic of cancer development, and the tumor's ability of avoiding immune destruction is recognized as an emerging hallmark of cancer [6] . Innate cells such as macrophages, mast cells and neutrophils contribute to tumor angiogenesis, and tumor infiltration by such cells often correlates with a poor prognosis [6, 7] . In contrast, an abundance of infiltrating lymphocytes often correlates with a favorable prognosis [7] .
While cell death by damage to tumor DNA is thought to be the main mode of action of radiotherapy, evidence suggests that, it in addition mobilizes tumor specific immunity and stimulates an antitumor response [8, 9] . Hence, radiotherapy can improve the effect of immunotherapy in cancer treatment [10] . Recent studies have also shown that the efficacy of high dose radiotherapy depends on the presence of CD8+ T cells [11, 12] . We previously reported on the prognostic impact of both innate and adaptive immune cell markers in NSCLC [13] [14] [15] . In addition, we have shown that angiogenic markers have prognostic impact in surgically resected NSCLC patients receiving postoperative radiotherapy (PORT) [16] . To the best of our knowledge, no studies have explored the prognostic significance of immune cell markers in this group of patients. In light of the link between radiotherapy and tumor specific immune responses, we aimed to explore if in situ immunity had an impact on survival in NSCLC patients treated with PORT.
Materials and methods

Patients
Patients surgically resected for NSCLC stage I-IIIA at the University Hospital of Northern Norway and Nordland Central Hospital from 1990 through 2004 were identified in this retrospective study. In total, 371 patients from the hospital databases were registered. Of these, sixty-three patients received radiotherapy within 12 weeks postoperatively, with a cumulative radiation dose of ≥50 Gy. Eight patients were excluded due to: Preoperative chemotherapy (n = 3), other malignancy within 5 years prior to NSCLC diagnosis (n = 3) or inadequate paraffin-embedded surgical specimens (n = 2). A total of 55 patients were thereby included in the study. Adjuvant chemotherapy had not been introduced in Norway during this period (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) . Clinicopathologic and demographic data were collected retrospectively. This study includes follow up data as of January 2011. Patients were staged according to the revised 7th edition of UICC TNM classification of lung cancer [17] , and histologically graded and subtyped according to the World Health Organization guidelines [18] . The Norwegian Data Inspectorate and The Regional Committee for Medical and Health Research Ethics approved the study.
Microarray construction
All specimens were examined by two pathologists (S.Al-S and K.Al-S). The most representative paraffin blocks were selected and two areas of viable tumor cells (neoplastic epithelium) and two from the central tumor-surrounding stroma were chosen and marked on the donor blocks. The tissue microarrays were assembled using a tissue-arraying instrument (Beecher Instruments, Silver Springs, MD, USA). The detailed methodology has been reported previously [19] . Using a 0.6 mm-diameter stylet, cores from two separate predefined neoplastic epithelial areas and two stromal areas were transferred to recipient blocks. To include all core samples, a total of eight tissue array blocks were constructed. Multiple 4-m sections were cut with a Micron microtome (HM355S) and stained with specific antibodies for immunohistochemical analysis. Both normal lung tissues localized distant to the primary tumor and one slide with normal lung tissue sample from 20 patients without a diagnosis of cancer were used as controls.
Immunohistochemistry
The following antibodies from Ventana Medical (Tucson, Ariz, USA) were used in this study: CD20 (clone L26), CD8 (clone 1A5), CD68 (clone KP1), CD138 (clone B-A38), CD1a, CD3 (clone PS1), CD117 (clone anti-C Kit, 9.7) and CD138 (clone B-A38). All Ventana antibodies were prediluted from the manufacturer. In addition CD4 (clone 1F6, Novocastra Laboratories Ltd. Newcastle upon Tyne, UK, dilution 1:5), M-CSF (Santa Cruz Biotechnology, Santa Cruz, CA, USA, dilution 1:5) and CSF-1R (clone H-300, Santa Cruz Biotechnology, dilution 1:25) were used. The detailed immunohistochemical procedures have been published previously [13] [14] [15] . For each antibody, including negative staining controls, all staining was done in a single experiment. As negative staining controls, the primary antibodies were replaced with the primary antibody diluents.
Scoring of Immunohistochemistry
Tissue sections were scored by light microscopy for degree of infiltration of the specified immune cells.
The CD8+ cells were scored as low if ≤5% or as high if >5% of the whole surface area of the epithelial compartments were infiltrated, and was scored as low if ≤50% or high if >50% of the total nucleated surface area of the stromal compartments were infiltrated. CD4+ cells were scored as high if representing ≥5% or ≥25% of the total nucleated cells in the epithelial and stromal compartments, respectively. Few CD4+ and CD8+ T cells (0 to <5% of the total nucleated cells) were observed in the interstitial tissue of the nonneoplastic controls.
CD1a+ cells were scored as low if absent or if representing <1% of the nucleated cells and high otherwise, in both epithelial and stromal compartments. Intraepithelial CD68+ cells were scored as low if absent or representing <1% of the nucleated cells and high otherwise, while the more abundant stromal CD68+ cells were scored as low if they represented <25% of the total nucleated cells and high otherwise. CD56+ cells were scored as present (high score) or absent (low score) in both epithelial and stromal compartments. The intensity of M-CSF and CSF-1R in both epithelial and stromal compartments were scored as follows: 0 = negative; 1 = weak; 2 = intermediate and 3 = strong. The cell density of the stroma was scored as the ratio of positive cells compared to the surface area of the extracellular matrix in the following manner: 1 = low density (<25% cell/matrix ratio); 2 = intermediate density (25-50%) and 3 = high density (>50%). High expression in the tumor epithelium was defined as a score ≥1.5 for both M-CSF and CSF-1R. Expression in the stroma was calculated by adding density score to intensity score prior to categorizing into low and high expression. High expression was defined as >3.5 for M-CSF and >3 for CSF-1R.
CD3+ cells were scored as low if they represented <1% of the nucleated cells in the epithelial cores and high otherwise, and as high if representing >50% of nucleated cells in the stroma and low otherwise. CD138+ cells were scored as high if representing >5% of the nucleated cells in the epithelial compartment or >25% in the stromal compartment, and as low otherwise. As CDD138+ cells also stain epithelial cells themselves the staining intensity in the epithelial compartment was scored in the following manner: 0 = negative; 1 = weak; 2 = intermediate and 3 = strong. High expression was defined as a score >1. CD117+ cells were extremely rare in the epithelial compartments and sparse in the stromal compartment, they were therefore scored as present (high score) or absent (low score) and only in the stromal compartment.
All samples were anonymized and independently scored by two pathologists (S.A.S and K.A.S). In case of disagreement, the slides were re-examined and the observers reached a consensus. When assessing one marker in a given core, both observers were blinded to the scores of the other markers as well as to the patient's outcome. The interobserver scoring agreement between the two pathologists was tested on the current material previously [20] , with a mean correlation coefficient of 0.95 (range 0.93-0.98).
Statistical methods
All statistical analyses were carried out using the statistical package IBM SPSS, version 20 (SPSS Inc., Chicago, IL, USA). Univariate analysis of the association between marker expression and survival was done using the Kaplan-Meier method and the statistical significance of differences between survival curves was assessed by the log-rank test. The disease-specific survival (DSS) was determined from the date of surgery to the time of lung cancer death. Only variables of significant value from the univariate analysis were entered into the multivariate analysis, using the Cox proportional hazards model. Probability for stepwise entry and removal was set at 0.05 and 0.10. The significance level was set at P < 0.05.
Results
Clinicopathologic variables
Demographic, clinical and histopathology variable are presented in Table 1 . The median survival time for all 55 patients was 24 months (range 3-197). The 5-year DSS was 44% and the 10-year DSS was 42%. Median patient age was 65 years (range 39-76) and the majority of patients were men (69%). The NSCLC tumors were comprised of 33 squamous cell carcinomas, 16 adenocarcinomas and 6 large cell carcinomas.
In univariate analysis, weight loss >10% (P = 0.029), histology (P = 0.048), poor tumor cell differentiation (P = 0.026) and nodal metastasis (P = 0.010) were significant prognostic variables ( Table 1) . The association between molecular marker expression and disease-specific survival data is presented in Table 2 . The coexpression of CD4 and CD8 was a strong significant prognostic factor ( Fig. 1 and Table 2 ), as was stromal CD4 expression (Table 2) . In addition, patients with high stromal expression of CD1a had a significantly better DSS than those with a low expression (Fig. 2) .
Multivariate analysis
None of the clinicopathologic variables emerged significant in multivariate analysis, while the hazard ratio was 21.2 (CI95% 4.5-120.4, P < 0.001) for the ↓CD4/↓CD8 combination and 1.8 (CI95% 0.4-8.4, P = 0.430) for other CD4/CD8 combinations, when compared to the reference group ↑CD4/↑CD8 (Table 3) . Low CD1a had a hazard ration of 2.5 (CI95% 0.97-6.2, P = 0.058) when compared to high expression. 
Discussion
We present the first study examining the prognostic impact of immune cell marker expression in surgically resected NSCLC patients treated with adjuvant radiotherapy. Our main finding is that the stromal co-expression of CD4+ and CD8+ T lymphocytes is a strong and independent prognostic factor in this group. Patients with ↓CD4+/CD8+↓ expression seem to have remarkably poor prognosis and will therefore most likely have a very limited benefit of adjuvant radiotherapy. The 5-year survival rate for patients with ↑CD4+↑CD8+ expression (16%, n = 9) was 78%, whereas ↓CD4+↓CD8+ patients (22%, n = 12) had median survival rate of only 9 months, with none surviving longer than 19 months from the time of diagnosis. The observed hazard ratio of 21.1 between ↓CD4+↓CD8+ and ↑CD4+↑CD8+ indicates a substantial and independent impact on DSS. However, due to the small number of patients the results have to be interpreted cautiously.
Hiraoka et al. have previously shown that there is a synergistic effect of simultaneous high CD4+ and CD8+ T-cell expression on survival in NSCLC [21] , while we previously showed that stromal expression of CD4 and CD8 both are independent prognostic factors in NSCLC [13] . The high hazard ratio observed in our subgroup of patients indicates that CD4/CD8 expression has higher prognostic significance in PORT treated patients, and may suggest a link between stromal in situ immunity and radiotherapy response.
Results from cell lines and murine models reveal close interplay between the immune system and the effects of radiotherapy. Radiotherapy may enhance expression of tumor-associated antigens, facilitate immune-mediated targeting of the tumor stroma and diminish the activity of regulatory T-cells. [4] . However, our results suggest that radiotherapy alone does not up-regulate the immune response sufficiently to inhibit tumor growth in ↓CD4/↓CD8 patients. In a murine model of melanoma, Lee et al. observed that the therapeutic effect of radiotherapy was dependent on CD8+ T-cells, since tumors of CD8 depleted mice became radioresistant [11] . Gupta et al. recently described how CD8+ T-cells are crucial for the effect of local high-dose radiotherapy, whereas CD4+ T-cells and macrophages were not [12] . Low stromal CD4/CD8 may indicate an insufficient level of these cells for a successful "boosting" of the radiotherapy effect. Stimulating the immune response via immunotherapy could therefore possibly augment the responsiveness to radiotherapy in those individuals lacking concurrent high CD4/CD8 levels in the tumor stroma. Experimental data suggest that radiotherapy and immunotherapy may have additive and synergistic effects. Reits et al. showed that radiotherapy prior to adoptive treatment with cytotoxic Tcells greatly enhanced the efficacy of the immunotherapy [10] . Takeshima et al. observed that local tumor irradiation augmented the therapeutic effect of Th1 cell therapy, accompanied by induction of cytotoxic T-lymphocytes in the tumor draining lymph nodes and tumor mass [22] . In a murine model of Lewis Lung Carcinoma, Yokouchi et al. reported greater efficacy when combining radiotherapy with an agonistic monoclonal antibody to ␣OX40 (CD134), which augments T-cell expansion and survival, when compared to either single treatment given separately [23] . Similar results were presented by Gough et al., with a significant portion of long-term tumor-free survivors [24] . Combining CTLA-4 blockade with radiation, Demaria et al. were able to induce an immune-mediated inhibition of metastases in a mouse model of breast cancer [25] . Similarly, Dewan et al. were able to induce an abscopal effect by combining fractionated radiotherapy with an anti-CTLA-4 antibody [26] . Adjuvant immunotherapy has shown encouraging results in NSCLC [27] , but few trials have looked at combining immunotherapy with radiotherapy. As the above presented pre-clinical studies indicate, this treatment combination may be an interesting approach for resected NSCLC patients. Though only shown in univariate analysis, we found that a higher expression of stromal CD1a+ DCs confer an increased DSS when compared to low expression for patients treated with PORT. DCs are professional antigen presenting cells, who can process and present tumor associated antigens and thereby activate adaptive immune cells [28] . Radiation-induced tumor cell death may be associated with the production of maturation signals for DCs [29] .
Teitz-Tennenbaum et al. observed that the efficacy of DC immunotherapy was enhanced by radiotherapy [30] . Increasing DC infiltration though immunotherapy could therefore be a potential strategy to improve survival in PORT treated patients.
In conclusion, we have shown that low CD4/CD8 expression is an independent negative prognostic factor in surgically resected NSCLC treated with PORT. Though our results are striking, they should be considered with caution, as the number of included patients is low. Nevertheless, further studies are pivotal in order to elucidate the potential significance of CD4/CD8 expression as a predictive marker in adjuvantly irradiated NSCLC.
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